John Mascarenhas, MD

Expert panelists consider the ongoing role of transplant for patients with myelofibrosis and discuss when it is more appropriate to explore systemic therapy options.

Closing out their discussion on the management of myelofibrosis, panelists highlight updated data with fedratinib and ruxolitinib, respectively.

A brief review of the biology of myelofibrosis, the potential for disease modification, and subsequent implications for treatment.

Key opinion leaders on myeloproliferative neoplasms review clinical data behind pacritinib therapy in the setting of myelofibrosis.

Switching their focus to myelofibrosis management, expert panelists reflect on clinical data behind momelotinib, a novel JAK2 inhibitor.

Shared insight on how a patient’s symptom burden can impact management strategies within essential thrombocytopenia and polycythemia vera.

Expert perspectives on the respective treatment landscapes of essential thrombocytopenia (ET) and polycythemia vera (PV) following the ASH 2022 Annual Meeting.

John O. Mascarenhas, MD, discusses current advancement in the treatment landscape of myelofibrosis.

John O. Mascarenhas, MD, discusses the potential clinical significance of pacritinib in patients with myelofibrosis.

John O. Mascarenhas, MD, discusses the investigation of pelabresib in myelofibrosis.

John O. Mascarenhas, MD, discusses the potential for pacritinib to address an unmet need in the treatment of patients with myelofibrosis.

John O. Mascarenhas, MD, discusses the promise of imetelstat in myelofibrosis.

John O. Mascarenhas, MD, discusses limitations with JAK inhibitors in myelofibrosis.

John O. Mascarenhas, MD, discusses ongoing clinical trials in myelofibrosis.

John O. Mascarenhas, MD, discusses approved and emerging treatment options in myelofibrosis.

John Mascarenhas, MD, associate professor of Medicine, Mount Sinai School of Medicine, discusses pacritinib in patients with myelofibrosis.

John Mascarenhas, MD, associate professor of Medicine, Mount Sinai School of Medicine, discusses the results from the interim analysis of the MPD-RC 112 study, which compared frontline pegylated interferon-alpha-2a with hydroxyurea in the treatment of patients with high risk polycythemia vera and essential thrombocythemia.